FDA recall record

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg recall — FDA D-0049-2021

Out-of-specification organic impurity results obtained during routine stability testing.

Class IIIclassification
D-0049-2021official record ID
Oct 28, 2020report date

Recall record at a glance

Official recordD-0049-2021
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmMylan Pharmaceuticals Inc.
Report dateOct 28, 2020
Recall initiation dateOct 2, 2020
Quantity10,695 bottles
LocationMorgantown, WV, United States

Official product description

Candesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDC 0378-3002-77) and b) 500-count bottles (NDC 0378-3002-05), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Why the product was recalled

Out-of-specification organic impurity results obtained during routine stability testing.

Distribution information

Nationwide within the United States

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.